This study reflects the incidence of different mediastinal masses in West Bengal with their clinicopathologic correlation.

No abstract

Ovarian carcinosarcoma is an extremely rare tumor with an incidence of <2%. A report of such a rare case in a 40-year-old multiparous woman is being presented here. The patient complained of abdominal pain and distension. Abdominal computed tomography revealed a variegated mass in the right adnexal region. The CA-125 level was 1635 U/ml. The patient underwent laparotomy and the tumor was removed. Microscopic examination of the tumor showed presence of both carcinomatous and sarcomatous elements. Immunohistochemical analysis revealed that the carcinomatous component was positive for cytokeratin and estrogen receptor and negative for progesterone receptor. The sarcomatous component was positive for vimentin. Ki-67 was positive in 60% cells. A final diagnosis of ovarian carcinosarcoma was rendered. This case is significant owing to extreme rarity of the tumor. Records of similar cases must be maintained for future reference with regard to impact of treatment protocol followed on prognosis.

A 45-years old man complained of hematuria, and subsequent examination and ultrasonography revealed a mass in the left kidney. Nephrectomy was performed and macroscopically an ill-defined pale-cream, irregular mass was identified which occupied predominantly the renal medulla. Histopathologic examination showed slit like tubular ducts lined by atypical cuboidal to polygonal cells and a marked desmoplastic stromal reaction. The diagnosis of collecting duct carcinoma was made. Patient is now doing well after 11 months of follow up.

COVID-19 has turned out to be a global pandemic within a very short period since its first origin in China in December2019. With the gradual increase in the mortality rate all over the world, there is an urgent need for an effectual drug. Though no clinically approved vaccine or drug is available until now but scientists are trying hard to identify potential antivirals to this new coronavirus. Several drugs like hydroxychloroquine, remdesivir, azithromycin etc. are put under evaluation in more than 300 clinical trials for the treatment of COVID-19. Few of them already show encouraging results. The main agent of disease progression of COVID-19 is SARS-CoV2/nCoV, which is believed to have ~89% genetic resemblance with SARSCoV, a coronavirus responsible for the massive outbreak in 2003. With this hypothesis, a recently developed in silico Human-nCoV network and potential COVID-19 spreader proteins, have been derived from the Human-SARS-CoV protein interactions using SIS model and fuzzy thresholding, followed by a potential FDA drugs target based validation. We then perform a two-way analysis to identify the potential drug targets of COVID-19. In the first analysis, we identify the complete list of FDA drugs for the 37 level 1 and 4948 level 2 spreader proteins in this network followed by the application of a consensus strategy. In the second analysis, the same consensus strategy is applied but on a curated overlapping set of key genes identified from COVID-19 symptoms, risk factors and clinical outcome. The applied consensus strategy in both the analysis reveals that Fostamatinib, a FDA approved drug, has the highest drug consensus score both in level 1 and level 2. Further analysis reveals that Fostamatinib also targets CYP3A4, a level 2 spreader protein and the most common target formost of the potential COVID-19 drugs. A subsequent docking study also reveals that Fostamatinib has also the highest docking score with respect to 6LU7, the crystal structure of COVID-19 main protease in complex with an inhibitor N3, in comparison to other potential drugs like hydroxychloroquine, remdesivir, favipiravir and darunavir. Our computational study suggests that Fostamatinib may also be considered as one of the potential candidates for further clinical trials in pursuit to counter the spread of COVID-19.